Upcoming Dividend • May 26
Upcoming dividend of HK$0.12 per share Eligible shareholders must have bought the stock before 02 June 2026. Payment date: 30 June 2026. Payout ratio is a comfortable 32% but the company is paying out more than the cash it is generating. Trailing yield: 6.9%. Within top quartile of Hong Kong dividend payers (6.9%). Higher than average of industry peers (3.4%). Reported Earnings • Apr 28
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.98 (up from CN¥0.92 in FY 2024). Revenue: CN¥27.9b (flat on FY 2024). Net income: CN¥2.47b (up 6.6% from FY 2024). Profit margin: 8.8% (up from 8.3% in FY 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to HK$6.70, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 9x in the Chemicals industry in Hong Kong. Total returns to shareholders of 116% over the past three years. Declared Dividend • Mar 28
Final dividend of HK$0.12 announced Shareholders will receive a dividend of HK$0.12. Ex-date: 2nd June 2026 Payment date: 30th June 2026 Dividend yield will be 6.2%, which is lower than the industry average of 8.1%. Sustainability & Growth Dividend is covered by earnings (28% earnings payout ratio) but not covered by cash flows (165% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 24% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 27
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.98 (up from CN¥0.92 in FY 2024). Revenue: CN¥27.9b (flat on FY 2024). Net income: CN¥2.47b (up 6.6% from FY 2024). Profit margin: 8.8% (up from 8.3% in FY 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 7.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Duyuru • Mar 26
Fufeng Group Limited, Annual General Meeting, May 29, 2026 Fufeng Group Limited, Annual General Meeting, May 29, 2026. Duyuru • Mar 16
Fufeng Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026 Fufeng Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026 Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$9.18, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 10x in the Chemicals industry in Hong Kong. Total returns to shareholders of 170% over the past three years. Buy Or Sell Opportunity • Sep 18
Now 21% undervalued Over the last 90 days, the stock has risen 33% to HK$9.37. The fair value is estimated to be HK$11.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 8.7%. Revenue is forecast to grow by 10% in 2 years. Earnings are forecast to grow by 4.1% in the next 2 years. Buy Or Sell Opportunity • Sep 02
Now 21% undervalued Over the last 90 days, the stock has risen 34% to HK$9.19. The fair value is estimated to be HK$11.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 8.7%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 4.8% in the next 2 years. Reported Earnings • Aug 31
First half 2025 earnings released: EPS: CN¥0.71 (vs CN¥0.41 in 1H 2024) First half 2025 results: EPS: CN¥0.71 (up from CN¥0.41 in 1H 2024). Revenue: CN¥14.0b (up 4.4% from 1H 2024). Net income: CN¥1.79b (up 72% from 1H 2024). Profit margin: 13% (up from 7.8% in 1H 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Declared Dividend • Aug 30
First half dividend of HK$0.36 announced Shareholders will receive a dividend of HK$0.36. Ex-date: 10th September 2025 Payment date: 30th September 2025 Dividend yield will be 6.3%, which is lower than the industry average of 8.1%. Sustainability & Growth Dividend is covered by both earnings (35% earnings payout ratio) and cash flows (66% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 28% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Aug 18
Fufeng Group Limited to Report First Half, 2025 Results on Aug 28, 2025 Fufeng Group Limited announced that they will report first half, 2025 results on Aug 28, 2025 Major Estimate Revision • Jul 23
Consensus EPS estimates increase by 15% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from CN¥0.993 to CN¥1.15. Revenue forecast steady at CN¥28.8b. Net income forecast to grow 24% next year vs 86% growth forecast for Chemicals industry in Hong Kong. Consensus price target up from HK$7.58 to HK$8.18. Share price rose 20% to HK$8.31 over the past week. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$7.90, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 8x in the Chemicals industry in Hong Kong. Total returns to shareholders of 135% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$5.50 per share. Upcoming Dividend • May 26
Upcoming dividend of HK$0.22 per share Eligible shareholders must have bought the stock before 02 June 2025. Payment date: 27 June 2025. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 6.0%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (3.7%). Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Fiona Li was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Declared Dividend • Mar 31
Final dividend of HK$0.22 announced Shareholders will receive a dividend of HK$0.22. Ex-date: 2nd June 2025 Payment date: 27th June 2025 Dividend yield will be 6.6%, which is lower than the industry average of 8.1%. Sustainability & Growth The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 23% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 30
Full year 2024 earnings: Revenues and EPS in line with analyst expectations Full year 2024 results: EPS: CN¥0.92 (down from CN¥1.24 in FY 2023). Revenue: CN¥27.8b (flat on FY 2023). Net income: CN¥2.31b (down 27% from FY 2023). Profit margin: 8.3% (down from 11% in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Mar 28
Fufeng Group Limited, Annual General Meeting, May 29, 2025 Fufeng Group Limited, Annual General Meeting, May 29, 2025. Buy Or Sell Opportunity • Mar 25
Now 21% undervalued Over the last 90 days, the stock has risen 14% to HK$6.21. The fair value is estimated to be HK$7.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 8.3% in 2 years. Earnings are forecast to grow by 5.6% in the next 2 years. Duyuru • Mar 18
Fufeng Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 Fufeng Group Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 Major Estimate Revision • Sep 05
Consensus EPS estimates fall by 19% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥28.9b to CN¥27.9b. EPS estimate also fell from CN¥1.19 per share to CN¥0.967 per share. Net income forecast to shrink 3.1% next year vs 24% growth forecast for Chemicals industry in Hong Kong . Consensus price target down from HK$6.22 to HK$5.90. Share price was steady at HK$4.30 over the past week. Reported Earnings • Aug 31
First half 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.61 in 1H 2023) First half 2024 results: EPS: CN¥0.41 (down from CN¥0.61 in 1H 2023). Revenue: CN¥13.4b (down 1.6% from 1H 2023). Net income: CN¥1.04b (down 32% from 1H 2023). Profit margin: 7.8% (down from 11% in 1H 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 20
Fufeng Group Limited to Report First Half, 2024 Results on Aug 29, 2024 Fufeng Group Limited announced that they will report first half, 2024 results on Aug 29, 2024 Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$4.40, the stock trades at a forward P/E ratio of 3x. Average forward P/E is 9x in the Chemicals industry in Hong Kong. Total returns to shareholders of 147% over the past three years. Upcoming Dividend • May 27
Upcoming dividend of HK$0.35 per share Eligible shareholders must have bought the stock before 03 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 7.2%. Lower than top quartile of Hong Kong dividend payers (7.6%). Higher than average of industry peers (4.7%). Declared Dividend • Mar 29
Final dividend of HK$0.35 announced Shareholders will receive a dividend of HK$0.35. Ex-date: 3rd June 2024 Payment date: 28th June 2024 Dividend yield will be 11%, which is higher than the industry average of 8.1%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (47% cash payout ratio). The dividend has increased by an average of 29% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 8.9% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Mar 28
Fufeng Group Limited, Annual General Meeting, May 30, 2024 Fufeng Group Limited, Annual General Meeting, May 30, 2024. Reported Earnings • Mar 28
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.52 in FY 2022). Revenue: CN¥28.0b (up 1.9% from FY 2022). Net income: CN¥3.14b (down 19% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 7.5% p.a. on average during the next 2 years, compared to a 8.4% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 27
Fufeng Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 Fufeng Group Limited proposed final dividend of HKD 0.22 per share for the year ended 31 December 2023. Date of shareholders' approval is 30 May 2024. Ex-dividend date is 03 June 2024. Record date is 07 June 2024. Payment date is 28 June 2024. Duyuru • Mar 16
Fufeng Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Fufeng Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024 Upcoming Dividend • Sep 11
Upcoming dividend of HK$0.23 per share at 13% yield Eligible shareholders must have bought the stock before 18 September 2023. Payment date: 13 October 2023. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 13%. Within top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (7.6%). Reported Earnings • Sep 01
First half 2023 earnings released: EPS: CN¥0.61 (vs CN¥0.80 in 1H 2022) First half 2023 results: EPS: CN¥0.61 (down from CN¥0.80 in 1H 2022). Revenue: CN¥13.6b (up 5.0% from 1H 2022). Net income: CN¥1.54b (down 24% from 1H 2022). Profit margin: 11% (down from 16% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 31
Fufeng Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 13 October 2023 Fufeng Group Limited announced Interim Dividend of HKD 0.23 per share for the six months ended 30 June 2023. Record date is 22 September 2023. Payment date is 13 October 2023. Ex-dividend date is 18 September 2023. Duyuru • Aug 19
Fufeng Group Limited to Report First Half, 2023 Results on Aug 30, 2023 Fufeng Group Limited announced that they will report first half, 2023 results on Aug 30, 2023 Duyuru • Aug 01
Fufeng Group Limited Announces Management Changes, Effect from 1 August 2023 The board of directors of Fufeng Group Limited announced that Mr. Lee Wai Yin (Mr. Lee) has tendered his resignation as company secretary and authorised representative of the Company with effect from 1 August 2023. The Board announced that Mr. Yau Wing Yiu (Mr. Yau) will be appointed as the company secretary and authorised representative of the Company with effect from 1 August 2023. Mr. Yau joined the Group as chief financial officer since June 2021. Mr. Yau is an associate member of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. The biography of Mr. Yau could be referenced to the 2022 annual report of the Company. Upcoming Dividend • May 29
Upcoming dividend of HK$0.33 per share at 13% yield Eligible shareholders must have bought the stock before 05 June 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 13%. Within top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (7.3%). Reported Earnings • Mar 31
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CN¥1.52 (up from CN¥0.51 in FY 2021). Revenue: CN¥27.5b (up 28% from FY 2021). Net income: CN¥3.86b (up 202% from FY 2021). Profit margin: 14% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Sep 02
Upcoming dividend of HK$0.37 per share Eligible shareholders must have bought the stock before 09 September 2022. Payment date: 07 October 2022. Payout ratio is a comfortable 8.9% and this is well supported by cash flows. Trailing yield: 4.3%. Lower than top quartile of Hong Kong dividend payers (8.2%). Lower than average of industry peers (6.1%). Reported Earnings • Aug 31
First half 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.23 in 1H 2021) First half 2022 results: EPS: CN¥0.80 (up from CN¥0.23 in 1H 2021). Revenue: CN¥12.9b (up 36% from 1H 2021). Net income: CN¥2.03b (up 243% from 1H 2021). Profit margin: 16% (up from 6.2% in 1H 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 9.7% while the Chemicals industry in Hong Kong is not expected to grow. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improved over the past week After last week's 21% share price gain to HK$5.03, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 39% over the past three years. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improved over the past week After last week's 16% share price gain to HK$4.33, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 27% over the past three years. Upcoming Dividend • May 30
Upcoming dividend of HK$0.12 per share Eligible shareholders must have bought the stock before 06 June 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 5.6%. Lower than top quartile of Hong Kong dividend payers (7.8%). In line with average of industry peers (5.4%). Reported Earnings • Apr 27
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥0.51 (up from CN¥0.25 in FY 2020). Revenue: CN¥21.5b (up 29% from FY 2020). Net income: CN¥1.28b (up 103% from FY 2020). Profit margin: 5.9% (up from 3.8% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Over the next year, revenue is forecast to grow 19%, compared to a 12% growth forecast for the industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Apr 06
Principal Founder & Executive Chairman recently bought HK$3.2m worth of stock On the 1st of April, Xuechun Li bought around 1m shares on-market at roughly HK$3.18 per share. This was the largest purchase by an insider in the last 3 months. This was Xuechun's only on-market trade for the last 12 months. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥0.51 (up from CN¥0.25 in FY 2020). Revenue: CN¥21.5b (up 29% from FY 2020). Net income: CN¥1.28b (up 103% from FY 2020). Profit margin: 5.9% (up from 3.8% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Over the next year, revenue is expected to shrink by 3.2% compared to a 8.3% growth forecast for the industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 26% share price gain to HK$3.09, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total loss to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 16% share price gain to HK$3.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 21% share price gain to HK$3.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improved over the past week After last week's 19% share price gain to HK$2.99, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total loss to shareholders of 5.9% over the past three years.